Roivant Sciences launched a 16th biopharma that immediately sourced and closed a potentially $1 billion-plus multi-program collaboration with Medigene to develop T-cell immunotherapies. Called Cytovant Sciences, the new venture was created by Roivant and spinout Sinovant Sciences to develop and commercialize cellular therapeutics in Asia that are deemed to potentially transform the treatment of diseases that are prevalent in Asian patients.
Cytovant has been granted exclusive licenses to develop, manufacture and commercialize Medigene’s research state T-cell immunotherapy targeting the cancer-testis antigen New York esophageal squamous cell carcinoma 1 (NY-ESO-1), as well as dendritic cell vaccine targeting Wilms Tumor-1 (WT-1) and potentially expressed Antigen in Melanoma (PRAME) antigens in Greater China, South Korea, and Japan according to GEN News.
Who is Roviant Sciences?
A biotech that builds subsidiary biotech and health technology companies. Roivant's initial strategy of in-licensing late-stage drug candidates through subsidiaries was later expanded to develop earlier stage drug candidates and other healthcare technologies through those same subsidiaries.
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).